Specialized Compositions for Promoting FGF21 Secretion in Niche Environments

Publication ID: 24-11857579_0004_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Specialized Compositions for Promoting FGF21 Secretion in Niche Environments,” Published Technical Disclosure No. 24-11857579_0004_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857579_0004_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,579.

Summary of the Inventive Concept

This inventive concept adapts the original composition for promoting FGF21 secretion to specialized, high-stress environments, such as high-altitude, disaster relief, high-security, and extreme physical stress situations.

Background and Problem Solved

The original patent disclosed a composition for promoting FGF21 secretion, but it did not address the unique challenges of specific, high-stress environments. The present inventive concept solves this problem by developing tailored compositions that thrive in these niche environments, thereby ensuring the effective promotion of FGF21 secretion.

Detailed Description of the Inventive Concept

The inventive concept comprises specialized compositions featuring Bifidobacterium bacteria adapted to specific, high-stress environments. For example, in high-altitude environments, the composition includes a Bifidobacterium bacterium adapted to thrive in low-oxygen conditions. In disaster relief settings, the composition is formulated for ease of transportation and storage in emergency situations. Similarly, in high-security environments, the composition is contained in a secure, tamper-evident package.

Novelty and Inventive Step

The new claims introduce novel, non-obvious adaptations of the original composition to address the specific challenges of high-stress environments. These adaptations, such as the selection of Bifidobacterium bacteria for their ability to increase FGF21 secretion in cold-stressed subjects or their containment in secure packages, demonstrate a clear inventive step beyond the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include compositions tailored to other high-stress environments, such as extreme temperatures, high-radiation areas, or isolated communities. Variations of the composition could also include different strains of Bifidobacterium bacteria or additional components to enhance their efficacy.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in industries catering to high-stress environments, such as military, aerospace, disaster relief, and high-security organizations. The compositions could be marketed as specialized nutritional supplements or pharmaceutical products, offering a unique value proposition to customers operating in these niche environments.

Field of Art

Microbiology, probiotics, and metabolic health, with expertise in bacterial strain selection, physiological stress response, and metabolic modulation techniques

Person of Ordinary Skill (PHOSITA) Profile

A researcher or biotechnologist with advanced degree in microbiology, familiar with probiotic strain characterization, metabolic pathway interactions, and environmental adaptation of bacterial species

Obviousness Rationale

A person skilled in the art would recognize that adapting Bifidobacterium breve M-16V to specific environmental conditions represents a predictable extension of the original patent's core methodology of using bacterial strains to modulate physiological processes. The variations demonstrate standard engineering approaches to optimize bacterial performance across different stress environments. These adaptations follow established scientific principles of strain selection and targeted compositional modifications.

Obvious Combinations & Variations

Source Patent Element
Bifidobacterium breve M-16V for promoting FGF21 secretion
PTD Variation
Selecting bacterial strain variants adapted to low-oxygen high-altitude environments
Obviousness Reasoning
Strain selection for environmental tolerance is a routine microbiological technique, and a PHOSITA would recognize predictable methods for identifying bacteria with enhanced stress resistance
Source Patent Element
Composition for metabolic modulation
PTD Variation
Formulating composition for disaster relief with enhanced transportability and storage stability
Obviousness Reasoning
Modifying delivery mechanisms for practical application represents an obvious design optimization within standard pharmaceutical and probiotic development practices
Source Patent Element
Method of administering Bifidobacterium for physiological modulation
PTD Variation
Targeting specific stress conditions like hypothermia or extreme physical activity
Obviousness Reasoning
Identifying bacterial strains with enhanced performance under specific physiological conditions is a predictable scientific approach using standard screening and selection methodologies
Source Patent Element
Bacterial composition in food or pharmaceutical formats
PTD Variation
Packaging in secure, tamper-evident containers for high-security environments
Obviousness Reasoning
Implementing specialized packaging is an obvious design choice for protecting sensitive biological compositions, following established pharmaceutical and biotechnology packaging standards
Source Patent Element
Bifidobacterium breve M-16V for metabolic regulation
PTD Variation
Selecting strains with enhanced cold-stress and metabolic response capabilities
Obviousness Reasoning
Identifying bacterial strains with improved stress response is a standard microbiological technique with predictable scientific methodologies for strain characterization
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed herein would be obvious to a person having ordinary skill in the art at the time of invention, as they represent predictable extensions of the foundational teachings in US Patent 11857579, involving routine microbiological strain selection, environmental adaptation, and compositional optimization techniques that would be apparent to a skilled practitioner in the field of probiotic development and metabolic modulation.

Original Patent Information

Patent NumberUS 11,857,579
TitleComposition for promoting the secretion of FGF21
Assignee(s)Morinaga Milk Industry Co., Ltd.